Literature DB >> 31863755

Preventive Strategy for Reexpansion Pulmonary Edema After Minimally Invasive Cardiac Surgery.

Koichi Inoue1, Arudo Hiraoka1, Genta Chikazawa1, Toshinori Totsugawa1, Kosuke Nakajima2, Mio Masuda2, Hidenori Yoshitaka1, Taichi Sakaguchi3.   

Abstract

Reexpansion pulmonary edema is a serious complication of minimally invasive cardiac surgery through the right minithoracotomy. As reexpansion mechanical injury and ischemia reperfusion injury to the collapsed lung are possible mechanisms, we introduced a preventive protocol that consists of intermittent ventilation of the right lung, restoration of bilateral ventilation, administration of mannitol before unclamping the aorta, and institution of mild hypothermia. Among 469 patients who underwent minimally invasive cardiac surgery, we used this protocol in 379 patients. Reexpansion pulmonary edema incidence decreased significantly from 7.8% to 2.1% (P = .006). Although further evaluation is required, our protocol may be effective in preventing reexpansion pulmonary edema.
Copyright © 2020 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31863755     DOI: 10.1016/j.athoracsur.2019.10.073

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Dexmedetomidine Improves Lung Function by Promoting Inflammation Resolution in Patients Undergoing Totally Thoracoscopic Cardiac Surgery.

Authors:  Junji Cui; Mintai Gao; Hongqian Huang; Xiaoyan Huang; Qingshi Zeng
Journal:  Oxid Med Cell Longev       Date:  2020-09-07       Impact factor: 6.543

2.  Outcome of Unilateral Pulmonary Edema after Minimal-Invasive Mitral Valve Surgery: 10-Year Follow-Up.

Authors:  Thomas Puehler; Christine Friedrich; Georg Lutter; Maike Kornhuber; Mohamed Salem; Jan Schoettler; Markus Ernst; Mohammed Saad; Hatim Seoudy; Derk Frank; Felix Schoeneich; Jochen Cremer; Assad Haneya
Journal:  J Clin Med       Date:  2021-05-29       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.